Literature DB >> 16960905

Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.

Lutz F Tietze1, Felix Major, Ingrid Schuberth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16960905     DOI： 10.1002/anie.200600936

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  11 in total

1.  A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.

Authors:  Mika Uematsu; Daniel M Brody; Dale L Boger
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

2.  Peptide modified mesoporous silica nanocontainers.

Authors:  Fabiola Porta; Gerda E M Lamers; Jeffrey I Zink; Alexander Kros
Journal:  Phys Chem Chem Phys       Date:  2011-06-07       Impact factor: 3.676

3.  Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

4.  Glucose conjugation for the specific targeting and treatment of cancer.

Authors:  Emilia C Calvaresi; Paul J Hergenrother
Journal:  Chem Sci       Date:  2013-06       Impact factor: 9.825

5.  A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Scott J Weir; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2012-06-12       Impact factor: 7.446

6.  Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.

Authors:  James P Lajiness; William M Robertson; Irene Dunwiddie; Melinda A Broward; George A Vielhauer; Scott J Weir; Dale L Boger
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

7.  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.

Authors:  Wei Jin; John D Trzupek; Thomas J Rayl; Melinda A Broward; George A Vielhauer; Scott J Weir; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2007-11-17       Impact factor: 15.419

8.  Investigation of the transformations of a novel anti-cancer agent combining HPLC, HPLC-MS and direct ESI-HRMS analyses.

Authors:  Lutz F Tietze; Birgit Krewer; Holm Frauendorf
Journal:  Anal Bioanal Chem       Date:  2009-07-31       Impact factor: 4.142

9.  Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065.

Authors:  Lutz F Tietze; Birgit Krewer; J Marian von Hof; Holm Frauendorf; Ingrid Schuberth
Journal:  Toxins (Basel)       Date:  2009-12-02       Impact factor: 4.546

10.  Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.

Authors:  Lutz F Tietze; Olaf Panknin; Birgit Krewer; Felix Major; Ingrid Schuberth
Journal:  Int J Mol Sci       Date:  2008-05-20       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.